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Introduction 
 
Body text begins 
 
Age – related macular degeneration (AMD) is a common ocular condition that may 
destroy central vision and has a devastating effect on the patient’s quality of life. 
More than eight million Americans, particularly those over the age of 55 years, suffer 
from age-related macular degeneration, and the overall prevalence of advanced 
AMD is projected to increase by more than 50% by the year 2030.1 In the UK, the 
annual incidence of neovascular AMD was calculated to be around 24,000 in 2005, 
with a prevalence of 243,000; this is predicted to rise to over 300,000 by 2025.2 The 
majority of patients with neovascular AMD progress to blindness in the affected eye 
within two years of diagnosis, and there is a 43% probability of progression to 
neovascular AMD in the other eye within five years.1 Until recently, the only 
pharmacological-based therapy for treatment of patients with neovascular 
degeneration has been photodynamic therapy with verteporfin.  
 
Although the pathophysiology is still poorly understood, it is increasingly clear that 
vascular endothelial growth factor (VEGF) plays an important role in promotion of the 
neovascularisation and vessel leakage that lead to loss of central vision. Therefore, 
intravitreal antiangiogenic therapy (injection of antiangiogenic agents directly into the 
vitreous) is currently the primary therapy for neovascular AMD. Currently, the most 
common therapeutic agents are ranibizumab, pegaptanib and bevacizumab (used 
off-label). Anti-VEGF agents administered systemically for other indications in 
oncology have been associated with serious systemic adverse events and death.(1) 
Since breakdown of the blood-ocular barrier is common in wet AMD, repeated 
Feldfunktion geändert
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intravitreal anti-VEGF therapy may lead to a small amount of systemic VEGF 
inhibition, possibly resulting in serious long-term adverse events, though these have 
not yet been shown in clinical studies.3 We here review the pathogenesis of the 
disease, the therapeutic options currently used in clinical practice and possible safety 






The leading journals that publish basic science and clinical research in the area of 
cardiovascular and ophthalmological diseases, and MEDLINE using PubMed, were 
scanned. The main terms used were “age-related macular degeneration”, 
“cardiovascular disease”, “ranibizumab”, “bevacizumab”, “pegaptanib” and “VEGF”. 
The publications were largely selected from the past five years, but older publications 
which are commonly referenced or highly regarded were not excluded. The reference 
lists of articles identified by this search strategy were screened and relevant articles 
were selected. Review articles are cited to provide the reader with information and 





Age-related macular degeneration 
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Early age-related macular degeneration is characterised by the presence of a few (< 
20) medium-size drusen or retinal pigmentary abnormalities. Intermediate age-
related macular degeneration is characterised by at least one large druse, numerous 
medium-size drusen, or by geographical atrophy that does not extend to the centre of 
the macula. As reviewed recently by de Jong,4 damage to the retinal pigment 
epithelium and a chronic aberrant inflammatory response can lead to large areas of 
retinal atrophy (called geographical atrophy), the expression of angiogenic cytokines 
such as vascular endothelial growth factor, or both. These processes may manifest 
as advanced AMD, which can either be non-vascular (dry, atrophic or non-exudative) 
or neovascular (wet or exudative). Advanced non-vascular AMD is characterised by 
drusen and geographical atrophy extending to the centre of the macula. Advanced 
neo-vascular AMD is characterised by choroidal neovascularisation and its 
sequelae.5 Figure 1 shows the fundus image of a patient with a large fibrosis as end 






Risk factors for AMD 
 
Several risk factors for the development and progression of AMD have been 
established in recent years, including advanced age, white race, heredity and a 
history of smoking. The prevalence of early AMD has been reported to increase from 
8% among people 43-54 years of age to 30% among people 75 years or older. 
Similarly, the prevalence of advanced AMD increases from 0.1% among people 43-
Formatiert:
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54 years of age to 7.1% among people 75 years or older. AMD is more common in 
whites than Hispanics or Asian persons, whereas blacks have the lowest prevalence 
of the disease.6 Data from the Human Genome Project revealed that polymorphisms 
in the complement factor H (CFH), complement factor B (CFB) and the complement 
component C2 genes may account for 75% of AMD cases.7 A polymorphism 
(Ala69Sr) on the age-related maculopathy susceptibility 2 gene (ARMS2 or 
LOC387715) has also been strongly associated with development of AMD.8  
Patients with a history of more than 10 pack-years of smoking have an 
increased risk for the development of AMD and even passive smokers also appear to 
have a doubled risk of AMD.9 Other modifiable risk factors for advanced AMD include 
arterial hypertension,10 obesity,11 high dietary fat intake12 and low plasma 




Cardiovascular risk factors 
 
Coronary heart disease (CHD) is the leading cause of mortality in the US and Europe 
for both men and women. Although in England and Wales mortality rates of CHD 
continue to fall among older age groups, the actual burden of coronary heart disease 
is increasing due to the ageing of the population.15 The rate of improvement in CHD 
mortality appears to be declining, and may even be reversing among younger 
women.15 Atherosclerosis is the underlying cause of most ischaemic events and can 
result in angina, myocardial infarction, congestive heart failure, cardiac arrhythmias 
or sudden cardiac death. Risk factors for cardiovascular disease (CVD) have been 
extensively reviewed in numerous publications.16-18 Data from the INTERHEART 
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study revealed that the major cardiovascular risk factors smoking, hypertension, 
hypercholesterolaemia, diabetes mellitus, abdominal obesity, sedentary lifestyle and 
several psychosocial factors account for >92% of cardiovascular events worldwide.18 
In the same study, daily consumption of fruits and vegetables, regular alcohol 
consumption and regular physical activity were associated with a reduced 
cardiovascular mortality. Most important, these findings were noted in men and 





Risk factors associated with CVD and AMD 
 
As early as the 1970s, researchers wondered whether AMD might be part of an 
underlying systemic vascular process or a result of factors that also influence the 
development of CVD.19,20 The Framingham Eye Study found an association between 
AMD and systemic blood pressure and its sequel left ventricular hypertrophy.20 The 
NHANES-I study reported a positive association between AMD and systemic 
hypertension, and between AMD and cerebrovascular disease.21 In a large 
population-based study, the odds ratio of carotid artery plaques was 4.7 times higher 
in patients with wet AMD, while peripheral arterial disease was associated with a 2.5 
times increased risk for AMD.22  
 
The potential link between AMD and CVD was highlighted further in two recent large 
US studies. The Atherosclerosis Risk in Communities (ARIC) study in more than 
10,000 patients demonstrated that subjects with late AMD were significantly more 
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likely to be diagnosed with incident coronary heart disease over 10 years than 
patients without late AMD (30.9% vs. 10.0%, respectively),23 and also showed a 
higher incidence of stroke (4.1% vs. 2.1%).24 The US Medicare Study, a population-
based cross-sectional and cohort study involving more than 1.5 million Medicare 
enrolees ≥ 65 years, found a 20% increased risk of incidental myocardial infarction in 
patients with neovascular AMD.25 Importantly, the Blue Mountains Eye Study, which 
included more than 3,600 baseline participants in a population-based cohort study of 
common eye diseases in an Australian population aged ≥ 49 years of age, 
demonstrated that early AMD predicted a doubling of cardiovascular mortality 
(relative risk [RR] 2.3, 95% confidence intervals [CI] 1.03 – 5.19) over the next 
decade after controlling for traditional risk factors.26 Late AMD predicted five-fold 
higher cardiovascular mortality (RR 5.57, 95% CI 1.35 – 22.99) and ten-fold higher 
stroke mortality (RR 10.21, 95% CI 2.39 – 43.6) after adjusting for age and gender 
only.26 Other studies, however, have found no relationship between AMD and 
CVD.27-33  
A potential link between AMD and cardiovascular disease would have 
important therapeutic implications given current concern that some intravitreal anti-
VEGF treatments for wet AMD could increase cardiovascular, and particularly 
cerebrovascular, risk.34  
Indeed, VEGF may be regarded as a double-edged sword. Although it is key 
in the pathogenesis of wet AMD, it at the same time plays a pivotal role in 
maintaining vascular integrity, particularly under conditions of ischaemia and hypoxia. 
Thus, any beneficial effects of anti-VEGF therapies in the eye must be weighed 
against potential long-term systemic effects of these agents, particularly when potent 
“pan”-anti-VEGF therapies such as ranibizumab and bevacizumab may exert 
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unwanted systemic extra-ocular effects due to the blocking of the cardioprotective 
functions of VEGF. 
The endothelium is increasingly recognised not only as a target (with vascular 
remodelling occurring in response to an injury and resulting in atherosclerosis), but 
as a mediator in the pathogenesis of vascular damage.35 Indeed, endothelial cells 
play an important homeostatic role in the cardiovascular system by the expression of 
numerous molecules and release of mediators such as nitric oxide (NO), superoxide 
and endothelin-1 (ET-1). Studies demonstrating dysfunction of these mediators in 
patients at risk or with fully developed forms of cardiovascular disease strongly 
suggest involvement of endothelium-derived factors in the pathogenesis of 
atherosclerosis and its sequelae.  
Functional alterations of the endothelial L-arginine / NO pathway may be 
important in cardiovascular disease since NO can inhibit substantially several 
components of the atherogenic process such as vascular smooth muscle cell 
contraction, proliferation and migration; platelet aggregation and adhesion; monocyte 
adhesion and oxidative modification of low-density lipoprotein (LDL). Hence, reduced 
endothelial NO release may accelerate the progression of atherosclerotic lesions. 
Most importantly, NO is the downstream mediator of VEGF and is considered an 
important defence system in maintaining vascular integrity.36 
VEGF was first described as a tumour-derived factor with potent ability to 
induce endothelial cell permeability,37 proliferation and angiogenesis.38,39 VEGF 
induces angiogenesis, and increases vascular permeability and inflammation: all of 
these are thought to contribute to the progression of the neovascular form of AMD. 
VEGF levels are raised in the retinal pigment epithelium and choroidal blood vessels 
of the macula and in the ocular fluid of most patients with proliferative diabetic 
retinopathy and retinal vein occlusion. 
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While VEGF occurs in several biologically active forms, a recombinant, 
humanised monoclonal antibody fragment (Fab), ranibizumab, neutralizes all forms 
of the growth factor. In 2006, two trials with ranibizumab showed that monthly 
intravitreal injections prevented vision loss and, in many cases, significantly improved 
the visual acuity of patients with neovascular AMD.40,41 Bevacizumab is another 
monoclonal antibody, like ranibizumab, that binds and inhibits all isoforms of VEGF, 
but with a lower affinity, and has a longer half-life compared to the fragment form. 
The Food and Drugs Administration (FDA) approved intravenous bevacizumab for 
patients with metastatic colorectal cancer in February 2004. The same year the first 
use of systemic bevacizumab for mostly bilateral neovascular AMD was reported.(2) 
Rapid regression of choroidal neovascularization was associated with a visual acuity 
improvement of 1-2 lines. A common adverse effect was an increase in systolic blood 
pressure (3,4). The studies were however too small to exclude other serious 
systemic complications, including increased risk of thromboembolic events, 
haemorrhage, proteinuria, wound healing complications, and gastro-intestinal 
perforation.(5) In 2005 the first report on the intravitreal use of bevacizumab in 
neovascular AMD was reported (6). The driving force for the “off-label” use of 
bevacizumab was in addition to its obvious clinical effectiveness (figure 2) its low 
price of less than 50 USD per intravitreal injection. In the meantime several 
retrospective and prospective studies indicate good functional outcomes (7-11) So 
far there has been no evidence for an increased risk for systemic adverse events, but 
studies are overall too small and follow-up is too short to fully evaluate potential 
systemic adverse events. Recent meta-analyses indicated functional outcomes and 
safety of bevacizumab comparable to ranibizumab (12,13). Several large prospective 
randomized clinical trials are currently ongoing comparing bevacizumab and 

























Gelöscht: the intravitreal 
use of bevacizumab to treat 
neovascular AMD has only 
been studied recently and is 
not approved by regulatory 
authorities worldwide.42,43
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systemic complications, including increased risk of thromboembolic events, 
hypertension, haemorrhage, proteinuria, wound healing complications and gastro-
intestinal perforation.44 Whether these systemic complications are relevant to wet 
AMD patients receiving very low doses by intravitreal injection is unknown. The 
widespread off-label use of bevacizumab is worrisome, particularly since clinically 
proven and available alternatives exist. The absence of systemic and ocular adverse 
events after three months’ therapy in the prospective clinical trial by Bashshur et al.43 
is reassuring, but the long-term safety of intravitreal bevacizumab remains to be 
established.  
Pegaptanib was granted marketing authorisation by the European Medicines 
Agency on 31 January 2006 for the treatment of neovascular AMD. Pegaptanib is a 
pegylated modified oligonucleotide that binds with high specificity and affinity to 
extracellular vascular endothelial growth factor (VEGF165), inhibiting its activity. 
VEGF165 is the VEGF isoform preferentially involved in pathological ocular 
neovascularisation. Pegaptanib blocks mainly VEGF165 reducing the growth of 
pathological blood vessels and associated bleeding and leakage. 
The main prospective clinical trials in patients with AMD have been conducted 
using pegaptanib and ranibizumab.40,41,45,46 Indirect comparison of pegaptanib and 
ranibizumab indicates an about 3-line difference in visual acuity outcomes in favour 
of ranibizumab. However, pegaptanib appears to be associated with fewer adverse 
effects although a direct comparison has never been studied. The three pivotal 
studies on ranibizumab reported a dose-related increased frequency of 
cardiovascular events (including stroke) and bleeding relative to the placebo group, 
although these increases were not statistically significant. 
Indeed, whilst these new treatments represent an important breakthrough in wet 
AMD management, the overall safety of intravitreal anti – VEGF drugs remains 
Gelöscht: It is of note that 
bevacizumab has not been 
approved for the treatment of 




seems to be somewhat less 
effective than ranibizumab 
but appears to be associated 
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unclear. First, although the drug is administered by injection through the sclera into 
the vitreous cavity, systemic absorption does occur, with potential for systemic 
adverse effects. In particular, human data are scant. Most importantly, since anti-
VEGF treatment is potentially required for years, chronic treatment, particularly with 
non-selective VEGF inhibitors may cause adverse effects that may only become 
clinically apparent over time. Second, because these trials were not designed to 
detect small differences in risk, much larger cohorts would be necessary to allow the 
evaluation of systemic adverse effects. In the reported clinical studies, the overall 
mortality rates were low given the advanced mean age of these populations (nearly 
80 years), this could be mainly due to the exclusion of patients with a history of, or 





Potential implications in AMD 
 
It is of note that VEGF, mostly through its downstream mediator NO, has many 
essential physiological functions in maintaining vascular integrity, including the 
potential formation of collateral vessels crucial for the maintenance of perfusion to 
ischaemic tissues, as in acute myocardial infarction, in particular.47 Intriguingly, while 
VEGF is crucial in maintaining vascular homeostasis, particular in clinical conditions 
associated with ischaemia and hypoxia, its role in maintaining plaque stability is 
currently a matter of debate.48 Conceptually, in view of the cardioprotective role of 
VEGF, non-selective “pan”-anti-VEGF antagonism with ranibizumab or bevacizumab 
Gelöscht: NEJM Wong 
letter: ref needed.
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could be of even greater concern than blocking VEGF with selective antagonists 
such as pegaptanib. However, whether and to what degree more selective VEGF 
inhibition translates into fewer unwanted systemic effects and thus results in better 
cardiovascular outcomes remains unproven. 
It is of note that cardiovascular safety of anti-VEGF drugs has not yet been 
addressed in randomised clinical trials. Unfortunately, the numbers of cardiovascular 
events in these AMD trials without pre-specified cardiovascular safety end points are 
too small to provide any clinical relevant evidence of safety. Indeed, the absence of 
evidence does not show evidence of absence. While trials for ranibizumab reported a 
marginally higher rate of arterial thromboembolic events in the higher dose treatment 
arm, this trend did not reach statistical significance.49 (These trials were not powered 
to detect small differences in risk.) The issue is complicated further by a recent 
retrospective reanalysis of systemic safety outcomes with ranibizumab, which did not 
use the full dataset but nevertheless showed a significant increase in non-ocular 
haemorrhage in treated patients compared with controls (p=0.01), suggesting some 
impairment of systemic VEGF function.50 Although the doses involved in intravitreal 
injections of anti – VEGF agents are smaller than intravenous doses, intravitreal 
injection leads to peak serum concentrations several orders of magnitude greater 
than physiological levels of VEGF (11-27 ng/ml vs. 100 pg/ml in healthy 
adults).(14,15) The potential capacity of both drugs, especially bevacizumab, to 
saturate circulating VEGF hints at the possibility of adverse systemic effects. 
Trials with the only selective inhibitor pegaptanib have not as yet shown any 
cardiovascular safety signals.45 Importantly, however, all trials both with less 
selective or “pan”-anti-VEGF agents were underpowered and thus it is not possible to 
rule out existing cardiovascular safety concerns. Uncertainty about the 
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systemic safety data become available. These adverse events may be explained by 
endothelial dysfunction induced by anti-VEGF drugs. 
 
Pan anti-VEGF therapy has shown to stabilize vision in about 95% of patients 
with neovascular macular degeneration compared to 70% with selective VEGF 
inhibition. The results are most impressive compared to laser-photocoagulation 15 
years ago, leading to an unselective destruction of the retina and a primary loss of 
vision in order to stop progression of neovascular AMD. This obvious benefit from an 
ophthalmologic perspective stands in contrast to potential cardiovascular risks. Only 
adequately powered randomised clinical trials that prospectively address 
cardiovascular safety will provide the evidence to show whether the proven benefits 
of VEGF antagonism in the eye may come at the cost of potential systemic adverse 
effects, particularly increasing atherosclerosis and its clinical sequelae. Until this trial 
evidence becomes available ophthalmologists should avoid continuous VEGF 
suppression by using individualized treatment protocols(16) and should synchronize 


















Gelöscht: It has been 
demonstrated that anti-
VEGF therapies can delay 
the loss of vision in patients 
with neovascular macular 
degeneration and in some 
cases they could also 
reverse the visual loss that 
had occurred. 
Gelöscht: Until this trial 
evidence becomes available, 
ophthalmologists and 
cardiologists should maintain 
their efforts to reduce the 
cardiovascular burden of 
patients with wet AMD.
Cardiovascular Risk in AMD treatment 
Page 14 of 19 
Subhead A
Cardiovascular Risk in AMD treatment 
Page 15 of 19 
References 
 
1. Pereg D, Lishner M. Bevacizumab treatment for cancer patients with 
cardiovascular disease: a double edged sword? Eur Heart J 2008;29:2325-6. 
2. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. 
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular 
degeneration twelve-week results of an uncontrolled open-label clinical study. 
Ophthalmology 2005;112:1035-47. 
3. Geitzenauer W, Michels S, Prager F, et al. Comparison of 2.5 mg/kg and 5 
mg/kg systemic bevacizumab in neovascular age-related macular 
degeneration: twenty-four week results of an uncontrolled, prospective cohort 
study. Retina 2008;28:1375-86. 
4. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab 
(Avastin) therapy for neovascular age-related macular degeneration: twenty-
four-week results of an uncontrolled open-label clinical study. Ophthalmology 
2006;113:2002 e1-12. 
5. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-
VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res 
Commun 2005;333:328-35. 
6. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings 
after an intravitreal injection of bevacizumab (avastin) for macular edema from 
central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9. 
7. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on 
intravitreal bevacizumab (Avastin) for neovascular age-related macular 
degeneration of different durations. Acta Ophthalmol Scand 2007. 
8. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin 
BN. Intravitreal bevacizumab for the management of choroidal 
neovascularization in age-related macular degeneration. Am J Ophthalmol 
2006;142:1-9. 
9. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. 
Intravitreal bevacizumab for treatment of neovascular age-related macular 
degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249-
256. 
10. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer 
M. Intravitreal bevacizumab in the treatment of neovascular age-related 
macular degeneration, 6- and 9-month results. Eye 2008;22:82-6. 
11. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) 
therapy versus photodynamic therapy plus intravitreal triamcinolone for 
neovascular age-related macular degeneration: 6-month results of a 
prospective, randomised, controlled clinical study. Br J Ophthalmol 
2008;92:356-60. 
12. Algvere PV, Kvanta A, Seregard S. Shall we use Avastin or Lucentis for ocular 
neovascularization? Acta Ophthalmol 2008;86:352-5. 
13. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic 
review on the effect of bevacizumab in exudative age-related macular 
degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11. 
14. Larsson A, Skoldenberg E, Ericson H. Serum and plasma levels of FGF-2 and 
VEGF in healthy blood donors. Angiogenesis 2002;5:107-10. 
Cardiovascular Risk in AMD treatment 
Page 16 of 19 
15. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related 
macular degeneration. Lancet 2007;370:204-6. 
16. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-
guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for 







1. Friedman DS, O'Colmain BJ, Munoz B et al. Prevalence of age-related 
macular degeneration in the United States. Arch Ophthalmol 2004;122:564-
72. 
2. Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and 
health resource utilisation of patients with neovascular age-related macular 
degeneration: results from the UK cohort of a five-country cross-sectional 
study. Br J Ophthalmol 2007;91:1303-07. 
3. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular 
neovascularization: promises and potential problems. JAMA 2005;293:1509-
13. 
4. de Jong PT. Age-related macular degeneration. N Engl J Med 2006;355:1474-
85. 
5. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J 
Med 2008;358:2606-17. 
6. Klein R, Klein BE, Knudtson MD et al. Prevalence of age-related macular 
degeneration in 4 racial/ethnic groups in the multi-ethnic study of 
atherosclerosis. Ophthalmology 2006;113:373-80. 
7. Gold B, Merriam JE, Zernant J et al. Variation in factor B (BF) and 
complement component 2 (C2) genes is associated with age-related macular 
degeneration. Nat Genet 2006;38:458-62. 
8. Kanda A, Chen W, Othman M et al. A variant of mitochondrial protein 
LOC387715/ARMS2, not HTRA1, is strongly associated with age-related 
macular degeneration. Proc Natl Acad Sci U S A 2007;104:16227-32. 
9. Khan JC, Thurlby DA, Shahid H et al. Smoking and age related macular 
degeneration: the number of pack years of cigarette smoking is a major 
determinant of risk for both geographic atrophy and choroidal 
neovascularisation. Br J Ophthalmol 2006;90:75-80. 
10. Risk factors for choroidal neovascularization in the second eye of patients with 
juxtafoveal or subfoveal choroidal neovascularization secondary to age-related 
macular degeneration. Macular Photocoagulation Study Group. Arch 
Ophthalmol 1997;115:741-7. 
11. Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index 
and the incidence of visually significant age-related maculopathy in men. Arch 
Ophthalmol 2001;119:1259-65. 
12. Seddon JM, Cote J, Rosner B. Progression of age-related macular 
degeneration: association with dietary fat, transunsaturated fat, nuts, and fish 
intake. Arch Ophthalmol 2003;121:1728-37. 
13. van Leeuwen R, Boekhoorn S, Vingerling JR et al. Dietary intake of 





Links:  0 pt, Erste






















Gelöscht: 1. Friedman 
DS, O'Colmain BJ, Munoz B 
et al. Prevalence of age-
related macular 
degeneration in the United 
States. Arch Ophthalmol 
2004;122:564-72.¶
2. Lotery A, Xu X, Zlatava 
G, Loftus J. Burden of 
illness, visual impairment 
and health resource 
utilisation of patients with 
neovascular age-related 
macular degeneration: 
results from the UK cohort of 
a five-country cross-sectional 
study. Br J Ophthalmol 
2007;91:1303-07.¶
3. van Wijngaarden P, 
Coster DJ, Williams KA. 
Inhibitors of ocular 
neovascularization: promises 
and potential problems. 
JAMA 2005;293:1509-13.¶
4. de Jong PT. Age-related 
macular degeneration. N 
Engl J Med 2006;355:1474-
85.¶
5. Jager RD, Mieler WF, 
Miller JW. Age-related 
macular degeneration. N 
Engl J Med 2008;358:2606-
Kommentar [FE: Below 
you find the references of the 
manuscript version, you sent 
to me. Above, you find the 
... [1]
... [2]
Cardiovascular Risk in AMD treatment 
Page 17 of 19 
14. VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, 
Palta M. Associations between antioxidant and zinc intake and the 5-year 
incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am 
J Epidemiol 1998;148:204-14. 
15. Allender S, Scarborough P, O'Flaherty M, Capewell S. Patterns of coronary 
heart disease mortality over the 20th century in England and Wales: Possible 
plateaus in the rate of decline. BMC Public Health 2008;8:148. 
16. Manson JE, Tosteson H, Ridker PM et al. The primary prevention of 
myocardial infarction. N Engl J Med 1992;326:1406-16. 
17. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary 
prevention of coronary heart disease in women. N Engl J Med 1995;332:1758-
66. 
18. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk 
factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet 2004;364:937-52. 
19. Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. Senile macular 
degeneration: a case-control study. Am J Epidemiol 1983;118:213-27. 
20. Kahn HA, Leibowitz HM, Ganley JP et al. The Framingham Eye Study. II. 
Association of ophthalmic pathology with single variables previously measured 
in the Framingham Heart Study. Am J Epidemiol 1977;106:33-41. 
21. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO. Factors associated 
with age-related macular degeneration. An analysis of data from the first 
National Health and Nutrition Examination Survey. Am J Epidemiol 
1988;128:700-10. 
22. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. 
Age-related macular degeneration is associated with atherosclerosis. The 
Rotterdam Study. Am J Epidemiol 1995;142:404-09. 
23. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related 
macular degeneration and risk of coronary heart disease: the Atherosclerosis 
Risk in Communities Study. Ophthalmology 2007;114:86-91. 
24. Wong TY, Klein R, Sun C et al. Age-related macular degeneration and risk for 
stroke. Ann Intern Med 2006;145:98-106. 
25. Duan Y, Mo J, Klein R et al. Age-related macular degeneration is associated 
with incident myocardial infarction among elderly Americans. Ophthalmology 
2007;114:732-7. 
26. Tan JS, Wang JJ, Liew G, Rochtchina E, Mitchell P. Age-related macular 
degeneration and mortality from cardiovascular disease or stroke. Br J 
Ophthalmol 2008;92:509-12. 
27. Risk factors for neovascular age-related macular degeneration. The Eye 
Disease Case-Control Study Group. Arch Ophthalmol 1992;110:1701-08. 
28. Delaney WV Jr, Oates RP. Senile macular degeneration: a preliminary study. 
Ann Ophthalmol 1982;14:21-4. 
29. Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its 
risk factors to age-related maculopathy. The Beaver Dam Eye Study. 
Ophthalmology 1993;100:406-14. 
30. Maltzman BA, Mulvihill MN, Greenbaum A. Senile macular degeneration and 
risk factors: a case-control study. Ann Ophthalmol 1979;11:1197-201. 
31. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other 
cardiovascular risk factors, and age-related maculopathy: the Blue Mountains 
Eye Study. Arch Ophthalmol 1998;116:583-7. 
Cardiovascular Risk in AMD treatment 
Page 18 of 19 
32. Vinding T. Age-related macular degeneration. An epidemiological study of 
1000 elderly individuals. With reference to prevalence, funduscopic findings, 
visual impairment and risk factors. Acta Ophthalmol Scand Suppl 1995:1:32. 
33. Vinding T, Appleyard M, Nyboe J, Jensen G. Risk factor analysis for atrophic 
and exudative age-related macular degeneration. An epidemiological study of 
1000 aged individuals. Acta Ophthalmol (Copenh) 1992;70:66-72. 
34. Liew G, Mitchell P. Ranibizumab for neovascular age-related macular 
degeneration. N Engl J Med 2007;356:747-8; author reply 749-50. 
35. Lüscher TF VP. The Endothelium: Modulator of Cardiovascular Function. 
Boca Ranton: CRC Press, 1990. 
36. El-Remessey AB, Tsai N, Caldwell RB. Is superoxide anion a mediator of 
vascular endothelial growth factor (VEGF) angiogenic function in retinal 
endothelial cells? Invest Ophthalmol Vis Sci 2003; 44: E-abstract 2913. 
37. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor 
cells secrete a vascular permeability factor that promotes accumulation of 
ascites fluid. Science 1983;219:983-5. 
38. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development 
and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9. 
39. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality 
induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42. 
40. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-
related macular degeneration. N Engl J Med 2006;355:1419-31. 
41. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for 
neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-
44. 
42. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on 
intravitreal bevacizumab (Avastin) for neovascular age-related macular 
degeneration of different durations. Acta Ophthalmol Scand 2007. Author, 
please complete this reference. 
43. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin 
BN. Intravitreal bevacizumab for the management of choroidal 
neovascularization in age-related macular degeneration. Am J Ophthalmol 
2006;142:1-9. 
44. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-
VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res 
Commun 2005;333:328-35. 
45. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. 
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 
2004;351:2805-16. 
46. Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab combined with verteporfin 
photodynamic therapy in neovascular age-related macular degeneration: year 
1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42. 
47. Ferrara N. Role of vascular endothelial growth factor in regulation of 
physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-66. 
48. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Antiangiogenic therapy 
for normalization of atherosclerotic plaque vasculature: a potential strategy for 
plaque stabilization. Nat Clin Pract Cardiovasc Med 2007;4:491-502. 
49. Summary of product characteristics. 
http:www.emea.europa.eu/humandocs/PDFs/EPAR/Lucentis/H-715-Pl-en.pdf 
50. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular 
degeneration. N Engl J Med 2007;356:748-9; author reply 749-50. 
Cardiovascular Risk in AMD treatment 
Page 19 of 19 
 




Age-related macular degeneration (AMD): the right eye (left image) shows a large 
fibrosis subsequent to untreated neovascular AMD. Visual acuity is counting 
fingers. The left eye (right image) has characteristic signs of a newly 




Optical coherence tomography (OCT): High resolution OCT allows an optical biopsy 
of the retina in cross section. The images shown are of the same patients as 
in figure 1. Before intravitreal injection of 1.25mg Bevacizumab (Avastin®) the 
upper images clearly indicates intraretinal edema and a choroidal 
neovascularization (CNV). One month following treatment intraretinal edema 
has completely resolved and the CNV has regressed.  
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